Ireland
--:--IST
Latest
Clinical Trials in France / NCT06324968
Active, not recruiting Not applicable

Ro60 Expression in Macrophages in Sjogren's Disease

NCT06324968 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-02-09
Last updated
2025-03-11

Condition(s) studied

Sjogren's Syndrome

Investigational drug(s) / intervention(s)

Positive serology for anti-SSA

Positive serology for anti-SSA: Blood sample which detect serology for anti-SSA.

Study summary

Context: The Ro60 protein associates with YRNAs (or RNYs) to form the RoRNP complex, which regulates RNA surveillance and maturation. It is hypothesized that its impairment by nuclear penetration of the anti-Ro60 autoantibodies, would deregulate the anti-inflammatory response in monocytes/macrophages (Mo/Mp) in patients with Sjögren's disease (SD).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with SSp Subjects aged between 18 and 75, without chronic disease; Subject meeting the classification criteria for SSp; Subject with positive anti-SSA serology; French-speaking subject able to give written consent; Subject affiliated to the Sécurité Sociale or an equivalent scheme; Subject willing to have blood samples taken; * Control subjects Subjects aged between 18 and 75, without chronic disease and not meeting SSp classification criteria; Subject who understands and speaks French and is able to give written consent; Subject affiliated to the French Social Security system or an equivalent scheme; Subject willing to have blood taken; Exclusion Criteria: * Subject receiving current anti-inflammatory treatment (e.g. corticosteroid therapy, non-steroidal anti-inflammatory drugs) or a regimen of more than 1 month within the last 3 months; * Subject undergoing biotherapy or cytoreductive treatment; * Subjects with positive serologies for human immunodeficiency virus (HIV), viral hepatitis B virus (HBV) and viral hepatitis C virus (HCV) in the 3 months preceding the inclusion visit; * Protected persons as defined in articles of the French Public Health Code.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Nice Nice Alpes-Mritimes

More Centre Hospitalier Universitaire de Nice trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06324968 on ClinicalTrials.gov ↗ ← All trials in France